Examining the Rift Between the Pharmaceutical Industry and the Pharmacy Profession: A Channels of Distribution Approach

REFERENCES

• Banks D. Pharmacists, pharmaceutical manufacturers, and conflicts of interest. Am J Health Syst Pharm. 2005; 62:1827–32.
   PubMedGoogle Scholar
• Facchinetti NJ, Dickson WM. Access to generic drugs in the 1950s: The politics of a social problem. Am J Public Health. 1982; 72:468–75.
   PubMedGoogle Scholar
• US Federal Trade Commission. Bureau of Consumer Protection. Drug product selection: Staff report to the Federal Trade Commission. Washington, DC: Bureau of Consumer Protection; 1979.
   Google Scholar
• Silverman M, Lee PR. The impossible dream: Search for the absolutely safe drug. In: Silverman M, Lee PR, eds. Pills, profits,, and politics. Berkeley and Los An-geles: University of California Press; 1974:81–106.
   Google Scholar
• Ascione FJ, Kirking DM, Gaither CA, Welage LS. Historical overview of ge-neric medication policy. J Am Pharm Assoc (Wash DC). 2001; 41:567–77.
   Google Scholar
• Levy R. The pharmaceutical industry: A discussion of competitive and antitrust issues in an environment of change. Washington, DC: Federal Trade Commission; 1999.
   Google Scholar
• Lewin T. Drug makers fighting back against advance of generics. Am J Hosp Pharm. 1987; 44:2189–97.
   Google Scholar
• Anon. The big lie about generic drugs. Consumer Rep. 1987; 52:480–5.
   Google Scholar
• Yesalis CE III, Levitz GS. The life and death of a field experiment: A case study of health care research in a hostile environment. J Health Polit Policy Law. 1985; 9:611–28.
   PubMedGoogle Scholar
• Hammond RW, Schwartz AH, Campbell MJ, et al. Collaborative drug therapy management by pharmacists-2003. Pharmacotherapy. 2003; 23:1210–25.
   PubMed Web of Science ®Google Scholar
• Ponedal SA. Pharmaceutical companies may not practice what they preach. Am J Hosp Pharm. 1987; 44:2253–4.
   PubMedGoogle Scholar
• Anon. State chapters react to drug companies' positions on therapeutic inter-change. ASHP. 1987; 44:2665–6.
   Google Scholar
• Feinberg IL. Therapeutic interchange and the pharmacist. Consultant Pharm. 1988; 3:405–6.
   Google Scholar
• Mossinghoff GJ. Opposition to therapeutic interchange. Am J Hosp Pharm. 1988; 45:1065.
   PubMedGoogle Scholar
• PhRMA. Comments of the Pharmaceutical Research and Manufacturers of America (PhRMA) on a proposal by the Washington State Department of Social and Health Services to change the basis of Medicaid reimbursement of pharmacists. Wash-ington, DC: Pharmaceutical Research and Manufacturers of America; 1997.
   Google Scholar
• Levy RA. Therapeutic substitution: The price of cost containment. Pharm Exec. 1986; (Apr):80–4.
   Google Scholar
• Kutikova L, Reed PJ. Who has an impact on collaborative drug therapy man-agement legislation? Perceptions of state pharmacy association directors. J Am Pharm Assoc (Wash DC). 2003; 43:261–4.
   Google Scholar
• Anon. When drug reps come calling. 2006. Change Online. www.hopkinsmedicine. org/mediall/Enews/drugreps.html (accessed 2006 Aug 11).
   Google Scholar
• Billi J, Krupansky F, Pearlman M, Stevenson J, Stross J. UMREIC Policy 01-04-008. Vendor visitation and interaction. March 2003. www.procurement.umich. edu/files/vendor_policy.pdf (accessed 2006 Aug 11).
   Google Scholar
• Zarowitz BJ, Muma B, Coggan P, et al. Managing the pharmaceutical indus-try-health system interface. Ann Pharmacother. 2001; 35:1661–8.
   PubMedGoogle Scholar
• Cipolle RJ, Strand LM, Morley PC. Outcomes of pharmaceutical care practice. In: Cipolle RJ, Strand LM, Morley PC, eds. Pharmaceutical care practice. New York: McGraw-Hill; 1998:205–35.
   Google Scholar
• Anon. Project demonstrates benefits of pharmacist care. America's Pharm. 2000; 122(3):39–40.
   Google Scholar
• Ernst ME, Doucette WR, Dedhiya SD, et al. Use of point-of-service health sta-tus assessments by community pharmacists to identify and resolve drug-related prob-lems in patients with musculoskeletal disorders. Pharmacotherapy. 2001; 21:988–97.
   PubMedGoogle Scholar
• Nau DP, Ponte CD. Effects of a community pharmacist-based diabetes patient-management program on intermediate clinical outcome measures. J Manage Care Pharm. 2002; 8(1):48–53.
   Google Scholar
• Anon. Impact of pharmaceutical care delivered in the community pharmacy set-ting: Results of a two year demonstration project. J Iowa Pharm Assoc. 2000; 18–24.
   Google Scholar
• Agrawal M, Thakkar N. Surviving patent expiration: Strategies for marketing pharmaceutical products. J Product Brand Manage. 1997; 6(5):305.
   Google Scholar
• Kaiser Family Foundation. 29 states join lawsuit alleging Bristol-Myers Squibb blocked generic competition for cancer drug. Kaiser Daily Health Policy Report. 2002; (June 5). www.kaisemetwork.org/daily reports/print report.cfm?DR_ID = 11539&dr_cat = 3 (accessed 2002 June 6).
   Google Scholar
• Harris G. Bristol-Myers fights to lock in patients for diabetes drug before generics hit. Wall Street Journal [serial online]. 2001 May 21. online.wsj.com/ PA2VJBNA4R/snippet/5B990390771921564522-search.html (accessed 2007 June 27).
   Google Scholar
• Abboud L. Drugmakers use new tactic to ding generic-drug firms. Wall Street Journal [serial online]. 2004 Jan 27. online.wsj.com/article_print/0„SB10751578402 9812090,00.html (accessed 2004 Jan 27).
   Google Scholar
• Harris G, McGinley L. FTC says drug firms misuse loopholes to delay generics. Wall Street Journal [serial online]. 2002 Jul 30. online.wsj.com/article/ SB102799250774947160.html?mod = health_home_top_story (accessed 2007 June 27).
   Google Scholar
• Anon. Generic drugs: The stalling game. Consumer Rep. 2001; 66:36–40.
   Google Scholar
• Saul S. Patent deal on a drug scrutinized. New York Times [serial online]. 2006 Jul 28. www.nytimes.com/2006/07/28/business/worldbusiness/28drug.html?ex = 1183089600&en = e74e18159101d8b0&ei = 5070 (accessed 2006 Jul 31).
   Google Scholar